These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26911408)

  • 1. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
    Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A
    Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
    Hebart H; Kiehl M; Tomasek J; Csoszi T; Koukakis R; Kafatos G; Kuhn A; Bjorklof K; Demonty G; Buchler T
    Adv Ther; 2019 Mar; 36(3):670-683. PubMed ID: 30689133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
    Hu H; Wang K; Huang M; Kang L; Wang W; Wang H; Qiu M; Lin R; Zhang H; Lan P; Wu X; Liu G; Wan Y; Liu M; Zhou Z; Huang Y; Li F; Zhang J; Cai Y; Ma T; Zhou J; Wang H; Ling J; Cai Y; Wu Z; Luo S; Ling L; Deng Y
    Oncologist; 2021 Jan; 26(1):e90-e98. PubMed ID: 33400355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in
    Modest DP; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; Fischer von Weikersthal L; Caca K; Kretzschmar A; Goekkurt E; Haas S; Kurreck A; Stahler A; Held S; Jarosch A; Horst D; Reinacher-Schick A; Kasper S; Heinemann V; Stintzing S; Trarbach T
    J Clin Oncol; 2022 Jan; 40(1):72-82. PubMed ID: 34533973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With
    Rossini D; Antoniotti C; Lonardi S; Pietrantonio F; Moretto R; Antonuzzo L; Boccaccino A; Morano F; Brugia M; Pozzo C; Marmorino F; Bergamo F; Tamburini E; Passardi A; Randon G; Murgioni S; Borelli B; Buonadonna A; Giordano M; Fontanini G; Conca V; Formica V; Aglietta M; Bordonaro R; Aprile G; Masi G; Boni L; Cremolini C
    J Clin Oncol; 2022 Sep; 40(25):2878-2888. PubMed ID: 35666229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.
    Kadowaki S; Masuishi T; Ura T; Sugiyama K; Mitani S; Narita Y; Taniguchi H; Muro K
    Int J Clin Oncol; 2021 Apr; 26(4):701-707. PubMed ID: 33386556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
    Kobayashi K; Yamaguchi S; Ito S; Torashima Y; Inoue Y; Okada S; Enjoji T; Tetsuo H; Kuba S; Kosaka T; Adachi T; Hidaka M; Yamanouchi K; Kanetaka K; Takatsuki M; Eguchi S
    Intern Med; 2020 May; 59(10):1239-1245. PubMed ID: 32074573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States.
    Gathirua-Mwangi WG; Sethi H; Afable MG; Bhattacharyya D; Khan T
    J Med Econ; 2021; 24(1):1164-1172. PubMed ID: 34529522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
    Elez E; Hendlisz A; Delaunoit T; Sastre J; Cervantes A; Varea R; Chao G; Wallin J; Tabernero J
    Br J Cancer; 2016 Feb; 114(4):372-80. PubMed ID: 26766738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
    Shinozaki K; Yamada T; Nasu J; Matsumoto T; Yuasa Y; Shiraishi T; Nagano H; Moriyama I; Fujiwara T; Miguchi M; Yoshida R; Nozaka K; Tanioka H; Nagasaka T; Kurisu Y; Kobayashi M; Tsuchihashi K; Inukai M; Kikuchi T; Nishina T
    Int J Clin Oncol; 2021 Feb; 26(2):399-408. PubMed ID: 33097971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
    Fernandez-Plana J; Pericay C; Quintero G; Alonso V; Salud A; Mendez M; Salgado M; Saigi E; Cirera L;
    BMC Cancer; 2014 Nov; 14():865. PubMed ID: 25417182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer.
    Chen B; Zheng D; Yu W; Huang C; Ye J; Han G; Zhuang J
    J Int Med Res; 2020 Sep; 48(9):300060520930440. PubMed ID: 32993393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer.
    Kito Y; Satake H; Taniguchi H; Yamada T; Horie Y; Esaki T; Denda T; Yasui H; Izawa N; Masuishi T; Moriwaki T; Mori K; Yamazaki K
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):277-284. PubMed ID: 32710148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).
    Sunakawa Y; Satake H; Usher J; Jaimes Y; Miyamoto Y; Nakamura M; Kataoka M; Shiozawa M; Takagane A; Terazawa T; Watanabe T; Ishiguro K; Tanaka C; Takeuchi M; Fujii M; Danenberg K; Danenberg PV; Lenz HJ; Sekikawa T; Ichikawa W
    ESMO Open; 2022 Jun; 7(3):100512. PubMed ID: 35688061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
    Kemeny NE; Chou JF; Capanu M; Chatila WK; Shi H; Sanchez-Vega F; Kingham TP; Connell LC; Jarnagin WR; D'Angelica MI
    Ann Surg; 2021 Aug; 274(2):248-254. PubMed ID: 33938493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial.
    Watanabe G; Mise Y; Oba M; Saiura A; Inoue Y; Takahashi Y; Kishi Y; Suyama K; Takayama T; Noie T; Nishioka Y; Akamatsu N; Arita J; Kokudo N; Hasegawa K
    HPB (Oxford); 2022 Aug; 24(8):1245-1251. PubMed ID: 35216869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?
    Yu IS; Loree JM
    Oncologist; 2021 Apr; 26(4):277-280. PubMed ID: 33539032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.